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Abstract
Background: Depression and depressive symptoms are highly prevalent in old persons but are potentially
reversible. Full recovery is the main goal in the treatment of depressive episodes. Compared to clinical trials,
observational studies of patients with depression in late life (DLL) show poorer prognoses in terms of response and
remission. However, observational studies on the course of DLL are scarce.
The aims of this study were to examine the course of DLL in terms of response, remission and symptom-specific
changes as measured by the Montgomery and Asberg Depression Rating Scale (MADRS), and to explore which
clinical variables were associated with the response and remission.
Methods: This is an observational, multicenter and prospective study of patients aged 60 years and older who
were referred to treatment of depression in the department of old-age psychiatry at specialist health care services
in Norway. The patients were evaluated with the MADRS at admission to and discharge from hospital. The mean,
median, minimum and maximum values for days stayed in hospital were 68, 53, 16 and 301, respectively.
Effect size (ES) was calculated to determine which MADRS symptoms changed most during the treatment. To
assess the predictors for change in the MADRS score (continuous variable) and for remission and response (both
dichotomous variables), regression models adjusting for cluster effects within center were estimated.
Results: Of 145 inpatients, 99 (68.3 %) had a response to treatment (50 % or more improvement of the MADRS
score). Remission (MADRS score ≤9 at discharge) was experienced in 74 (51.0 %) of the patients. Of the individual
MADRS items, “reported sadness” (ES =0.88) and “lassitude” (ES = 0.80) showed the greatest amount of
improvement, and “concentration difficulties” (ES = 0.50) showed the least amount of improvement during
treatment. Having a diagnosis of dementia was associated with a lower remission rate and less improvement in the
MADRS score during the treatment. Poorer physical health was associated with a lower response rate. Having
experienced previous episode(s) of depression was associated with a lower remission rate.
Conclusions: Recurrent episodes of depression, poor somatic health and a diagnosis of dementia were found to
be negative prognostic factors for the course of DLL. Clinicians should therefore pay close attention to these factors
when evaluating treatment.
Trial registration: ClinicalTrials.gov NCT01952366.
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Background
Depression and depressive symptoms are highly preva-
lent in old persons and pose global challenges [1]. De-
pression in late life (DLL) is associated with medical
comorbidity, dementia, functional impairment, reduced
quality of life, suicidal behavior, increased mortality and
increased service utilization [2–6].
Depressive episodes in old persons are potentially re-
versible, and full recovery is the main goal of treatment
[7]. Compared to clinical trials, prospective observa-
tional studies of inpatients have shown lower recovery
rates from depressive episodes in old persons, varying
from 38–69 % [8, 9]. Studies have also shown that 50 %
of patients with DLL can be partial- or non-responders
to initial treatment [7]. However, patients with DLL
have the same response and remission rates with
pharmacotherapy and electroconvulsive therapy (ECT)
as younger depressed patients, but relapse rates are
higher [10]. A clinical profile of an old depressed pa-
tient with conditions such as comorbid anxiety, psych-
otic symptoms, poor self-esteem, poor sleep, medical
comorbidity and coexisting cognitive impairment is as-
sociated with a poorer prognosis in terms of response
and remission [7, 11]. Partial response to treatment of
depressive episodes increases the risk of poor outcome
in terms of relapses, medical comorbidity and suicide
[11]. Guidelines for diagnosing and managing DLL [12]
as well as strategies for improving recovery rates have
been developed [7].
DLL often shows a heterogenous symptom profile
[11, 13]. A study of symptoms of DLL showed that the
items “depressed mood” and “loss of interest in work
and activities” showed the most improvement on the
Hamilton Rating Scale for Depression (HRSD) during
treatment [14].
The Montgomery and Asberg Depression Rating Scale
(MADRS) is designed to be sensitive to treatment effects
[15]. The scale has high inter-rater reliability and is a
valid tool for use in populations with DLL [15–17]. Sev-
eral studies have used the MADRS to evaluate the treat-
ment effects of DLL [9, 17, 18].
In Norway, most of the patients with DLL are treated in
primary care. However, patients who do not respond to
treatment in primary care and those with high medical
complexity, diminished ability to take care of themselves,
or severe depression (e.g. depression with psychosis or a
high risk of suicide) can be referred for treatment to de-
partments of old-age psychiatry in specialist health care as
inpatients. Such departments of old-age psychiatry are
well-established throughout the country and typically offer
services to catchment areas with 15,000 to 30,000 older
people above the age of 65 years. The number of beds at
these departments varies, but is recommended to be be-
tween 0.8 and 1.2 beds per 1,000 older people [19].
According to the latest edition of the Oxford textbook
of Old Age Psychiatry, purely observational data on the
course of DLL are scarce [20], and we are not aware of
any such study from the Nordic countries.
It is essential to have knowledge about how the indi-
vidual depressive symptoms of DLL change during
treatment [14]. The assessment of depressive symptoms
is dependent on the scale that is used. To our know-
ledge, no previous study has focused on the symptom-
specific changes as measured by MADRS during the
treatment of DLL. To learn more about the course of
DLL in hospitalized patients we have conducted a
multicenter, prospective observational study entitled
“Prognosis of Depression in the Elderly” (PRODE) in
Norway. The aims of this study were 1) to examine the
course of DLL during the stay in hospital in terms of
response and remission at discharge, 2) to identify
which clinical predictors were associated with these
outcomes, and 3) to investigate which individual de-
pressive symptoms showed greatest amount of change
during treatment, as measured by the MADRS.
Methods
Design
PRODE is an observational Norwegian multicenter pro-
spective study. Nine departments of old-age psychiatry
(Innlandet Hospital Trust; Sanderud and Reinsvoll,
Vestre Viken Hospital Trust; Lier, St. Olav Hospital; Uni-
versity Hospital of Trondheim; Oslo University Hospital;
Ullevaal and Aker, Haukeland University Hospital; Bergen,
Diakonhjemmet Hospital; Oslo and Stavanger University
Hospital; Stavanger) participated in the study. The collec-
tion of data was performed by health professionals work-
ing in these departments. Standardized assessment scales
were used. Assessors received standardized training prior
to the study period and again twice a year during the study
period in order to secure reliable data.
The patients
Patients were eligible for inclusion if they were 60 years or
older and had been referred to treatment for depression in
the departments of old-age psychiatry at specialist psychi-
atric health services. Patients with life-threatening diseases
as well as patients with dementia who had severe aphasia
were excluded from the study.
Attrition
The entire PRODE sample included 169 patients. In the
present study, 24 patients were excluded (nine because
they were outpatients and 15 due to incomplete MADRS
records), leaving 145 inpatients in this study. There were
no differences between the excluded and included pa-
tients regarding demographic and clinical characteristics
as described in Table 1, except for marital status (there
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was a greater amount of single people among the in-
cluded patients) and duration of depression (more pa-
tients with a duration of current depression of 13 weeks
or more among the excluded patients).
Representativeness
To assess representativeness, five of the nine study cen-
ters were able to collect data on age and gender from all
eligible patients invited to participate in the study, and
also to those who declined to participate. In these five
study centers, 159 patients were approached and 34
refused to participate in the study. There were no differ-
ences in age or gender between those who participated
in the study and those who refused to participate.
Procedures
Data was collected from December 2009 to July 2013. Pa-
tients were assessed for eligibility and included as early as
possible after admission. The mean number of days from
admission to inclusion was 5.7 days (SD = 6.0). Patients
were diagnosed with depression and dementia according
to the criteria of the Tenth Revision of the International
Classification of Diseases and Health Related Problems
(ICD-10) [21]. Discharge from the department of old age
psychiatry was not settled according to a standard proced-
ure, but according to the clinical procedure of the individ-
ual departments. The discharge assessment was carried
out as near as possible to the discharge date.
Measurements
Information on prior depressive and psychiatric history,
including the number of previous depressive episodes
and age at onset of the first lifetime depressive episode,
was obtained from case notes and structured interviews
with the patients and caregivers. The MADRS, a meas-
urement of the severity of depression, was the primary
outcome in the study. The MADRS consists of 10 items,
each rated from 0 points (no symptoms) to 6 points (se-
vere symptoms), with higher score denoting more severe
depression [15].
Cognitive function was evaluated by the Mini-Mental-
State Examination (MMSE), (score range 0–30) [22]. A
higher score indicates better cognition.
Anxiety symptoms were assessed by the seven-item
anxiety portion of the Hospital Anxiety and Depression
Scale (HADS-A) (score range 0–21) [23]. A higher score
denotes more severe symptoms.
Physical health was rated with the General Medical
Health Rating scale (GMHR), a four-point (excellent,
good, fair, and poor) global rating scale for medical over-
all comorbidity. The GMHR takes into account each pa-
tient’s number of general medical conditions, the
severity of those conditions and the patient’s use of med-
ications [24]. For the analyses, the GMHR was dichoto-
mized to good (excellent/good) and poor (fair/poor).
The instrumental activities of daily living (IADL) were
evaluated by using the Lawton and Brody scale [25].
This scale consists of five items for males and eight for
females. Each item was dichotomized (0 or 1) in line
with the original publication [25]. We generated a mean
score by dividing the IADL sum score by 5 for males
and 8 for females. A higher score denotes a higher level
of functioning (maximum score is 1 and minimum is 0).
Table 1 Demographic and clinical characteristics of the sample
(n = 145, if not specified)
Variable Value
Age, mean (SD) 75.9 (6.7)
Female, n (%) 106 (73.1)
Years of education (n = 138), mean (SD) 10.1 (3.1)
Days of stay, mean (SD) 68.3 (46.8)
Marital status
- Not-single (married/living together), n (%) 62 (42.8)
- Single (widow(er)/divorced/living apart), n (%) 83 (57.2)
GMHR1 categories (%)
- Good (very good/good) 74 (51.0)
- Poor (fair/poor) 71 (49.0)
Cognitive function, mean MMSE2 (n = 140), mean (SD) 25.9 (3.6)
MMSE, categories (n = 140)
- MMSE < 26 (%) 40.7
- MMSE≥ 26 (%) 59.3
Diagnosis of dementia, n (%) 13 (9.0)
Number of drugs, mean (SD) 5.9 (3.1)
Number of psychotropic drugs, mean (SD) 2.1 (1.4)
Activities of daily living (IADL)3 (n = 143)
- IADL per item score, mean (SD) 0.69 (0.26)
HADS-A4, mean (SD) (n = 141) 11.5 (4.7)
Age at onset of the first lifetime depressive
episode, in categories (n = 140)
- <60 years (%) 48.6
- ≥60 years (%) 51.4
Duration of depressive episode, categories (n = 142)
- <13 weeks (%) 47.2
- ≥13 weeks (%) 52.8
Previous depressive episode(s), n (%) 101 (69.7)
Mean MADRS5 score (SD) at inclusion 26.1 (8.6)
Bipolar diagnosis (ICD-10), n (%) 10 (6.9)
Depression with psychosis (ICD-10), n (%) 15 (10.3)
Patients with personality disorder (ICD-10), n (%) 3 (2.1)
1GMHR = General Medical Health Rating Scale
2MMSE =Mini Mental Status Examination
3IADL = Lawton Instrumental Activities of Daily Living Scale
4HADS = Hospital Anxiety and Depression Scale
5MADRS =Montgomery and Asberg Depression Rating Scale
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Marital status was dichotomized to not-single (includ-
ing married or living together) and single (including
widow [er], divorced or living apart).
Age at the onset of the first lifetime depressive episode
was dichotomized to 59 or earlier and 60 or later, as de-
scribed in other studies [26]. The number of previous
depressive episodes was dichotomized to no previous de-
pressive episodes or previous depressive episode(s). The
duration of the current depressive episode was dichoto-
mized to 12 weeks or shorter and 13 weeks or longer.
We classified the medications used according to the
Anatomical and Therapeutic Chemical (ATC) classifica-
tion system. In the ATC system, the active substances
are divided into different groups according to the organ
or system on which the substances act and their thera-
peutic, pharmacological and chemical properties. Dos-
ages of the various psychotropic drugs were calculated
by using Defined Daily Dose (DDD), the World Health
Organization’s (WHO) statistical measure of drug con-
sumption that gives the assumed average maintenance
dose per day for a drug that is used for its main indica-
tion in adults. The use of the ATC classification system
and DDD as a measuring unit is recommended by the
WHO for drug utilization studies [27].
Data on the MADRS and the patient’s use of medica-
tions were collected at the time of patients’ inclusion in
the study and at discharge from the department. Data
on the GMHR, IADL, HADS-A and MMSE were col-
lected at inclusion.
Outcomes
In line with previous recommendations for outcomes in
clinical studies of depression [28, 29] and an observa-
tional study of DLL using the MADRS, [9], remission
was defined by a score of ≤ 9 on the MADRS at the time
of discharge. Response was defined as a reduction of at
least 50 % in the MADRS score from time of inclusion
to discharge [18, 28].
Treatment
Patients were not assigned to a particular treatment
protocol. Treatment depended on patients’ needs and
practices at the local study center. Treatment was multi-
disciplinary, and virtually all patients received a mix of
individualized medication therapy, environmental ther-
apy, different psychotherapeutic approaches, physical ex-
ercise and social-/ economic oriented facilitation.
The mean, median, minimum and maximum values
for days of stay in hospital were 68.3, 53.0, 16, and 301,
respectively. The use of psychotropic drugs at time of in-
clusion and discharge is shown in Table 2. Thirty-eight
of the 145 patients (26.2 %) were treated with ECT. The
mean number of ECT treatments was 12.7 (SD = 6.2).
Other types of treatment were not rigorously quantified.
However, 31 % had individualized psychotherapy, 100 %
had individual supportive-based conversations, 92 % had
focus on social/- economic facilitation, 97 % had regular
physical exercise as part of the treatment and 63 % par-
ticipated in some kind of group therapy.
Statistical analysis
Data was analysed using the Statistical Program for So-
cial Science package (SPSS v. 22.0) and Statistical Ana-
lysis System (SAS v. 9.3).
Independent samples t-test or χ2-test were used to as-
sess the differences in age and gender between the pa-
tients who refused to participate and those patients who
were included in the PRODE study, and to compare the
clinical and demographic characteristics between the ex-
cluded and included patients in the analyses of this
paper. The change in use of psychotropic drugs from in-
clusion to discharge was assessed using McNemar’s test.
The t-test for paired samples was applied to assess the
change in DDD and MADRS score from inclusion to
discharge.
Some records of the IADL items were missing in 22 of
the 145 patients. Missing scores on IADL items were im-
puted for patients with 50 % or fewer missing values.
The imputation was performed separately for males and
females by drawing one random number per missing
value from the distribution of a specific item, estimated
on the available data.
Effect size (ES) was calculated to determine which
MADRS symptoms changed most during the treatment.
The use of ES for this purpose has previously been de-
scribed [30]. In the present analyses we used Cohen’s d.
As the study was performed concurrently at several dif-
ferent centers, a hierarchical structure might be present
in the data. According to an intra-class correlation coef-
ficient, the porportion of the variance within a centre
(cluster effect) was estimated to vary between 0.6 % and
12.0 % for MADRS symptoms. Hence, the standard devi-
ation (SD) was adjusted for cluster effect by estimating
an empty mixed linear model with random effects for in-
tercepts (SAS MIXED procedure). The ES (Cohen’s d)
for the specific MADRS symptoms was calculated by
dividing the mean change in score by the SD, which was
adjusted for cluster effect. Effect sizes greater than 0.80
are considered large, while those between 0.50 and 0.79
are moderate, and those less than 0.50 are small [31].
To assess the predictors for change in the MADRS
score (continuous variable) and for remission and re-
sponse (both dichotomous variables), regression models
adjusting for cluster effect caused by sampling from sev-
eral centers were estimated. A linear mixed model with
random effects for intercepts was estimated for continu-
ous outcomes (SAS MIXED procedure). For dichotmous
outcomes, logistic regression models for hierarchical
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data with random effects for intercepts were fitted (SAS
GLIMMIX procedure). Bivariate models were first esti-
mated for each predictor (MMSE, HADS-A, number of
drugs, IADL score, previous depressive episode(s), diag-
nosis of dementia, age at onset of the first lifetime de-
pressive episode, duration of current depressive episode,
GMHR and psychotic depression) and confounder (age,
years of education, gender, marital status and days of
stay in hospital). Then multivariable models, including
all predictors and confounders, were estimated. Akaike’s
Information Criterion (AIC) was then applied to elimin-
ate the redundant predictors. A smaller value of AIC
means a better model. Results with p-values below 0.05
were considered statistically significant.
Ethical and legal considerations
The participating patients and caregivers were given oral
and written information, and they subsequently gave
consent to participate in writing. For patients without
the capacity to give consent, their next of kin had to give
consent in writing on behalf of the patient. The study
was approved by the Regional Committee of Medical Re-
search Ethics and the Privacy and Data Protection Officer
at Oslo University Hospital. Trial registration: Clinical-
Trials.gov NCT01952366.
Results
Of the 145 patients included in the study, 106 (73.1 %)
were females. The mean age for all participants was 75.9
(SD = 6.7) years. The mean age was 76.2 (SD = 7.0) for
females and 75.1 (SD = 5.8) for males. Further demo-
graphic and clinical characteristics of the study popula-
tion are shown in Table 1. None of the patients died or
withdrew their consent during the study period.
At the time of inclusion in the study 74.5 % of the
patients used antidepressants, compared to 84.1 % at
discharge (p = 0.02). In addition, 2.1 % used anti-
dementia drugs at inclusion, compared to 7.6 % at dis-
charge (p = 0.02). No significant changes in the use of
other psychotropic drugs from inclusion to discharge
were found. Psychotropic drugs were used by 91.7 %
and 95.2 % of patients at inclusion and at discharge,
respectively (p = 0.27). The DDD among those patients
using antidepressants increased from 1.48 (SD = 0.91) at
inclusion to 1.74 (SD = 0.93) at discharge (p = 0.001). For
other psychotropic drugs, there were no differences in
DDD among those using the drug at both time points.
At inclusion, two of the 145 patients (1.4 %) resided in
a nursing home. Of the remaining 143 patients living in
their own homes at inclusion, 50 (35.0 %) received
domiciliary care. At inclusion, 57 of 140 patients (40.7
%) had a MMSE score of 25 or lower. Thirteen of the
145 patients (9.0 %) had a diagnosis of dementia estab-
lished during their stay. The mean MMSE score at inclu-
sion among these patients was 20.1 (SD = 3.6). Fifteen of
the 145 patients (10.3 %) were discharged to a nursing
home, 125 (86.2 %) to their homes and five (3.4 %) to
“other”, e.g. patients receiving care as inpatients at a
lower level of care. Seventy-five of the patients (51.7 %)
received further psychiatric treatment from specialist
health care as outpatients after discharge.
The mean MADRS score decreased from 26.1 (SD = 8.6)
at inclusion to 10.7 (SD = 7.9) at discharge (p < 0.001).
According to our definitions of response and remission,
74 of the 145 patients (51.0 %) experienced a remission,
and 99 (68.3 %) responded to treatment. Of the 99 pa-
tients who responded to treatment, 31 (31.3 %) were
not in remission at discharge. Of the total study popu-
lation of 145 patients, 68 (46.7 %) both responded to
treatment and experienced a remission.
The mean MADRS item scores at inclusion, the
change in mean MADRS item scores, and the effect
sizes for the MADRS items are all presented in Table 3.
The MADRS items of “reported sadness” (ES = 0.88) and
“lassitude” (ES = 0.80) showed the greatest effect sizes
and “concentration difficulties” (ES = 0.50) showed the
lowest effect size during treatment.
Results of the regression models for change in the
MADRS score, response and remission as dependent
variables are presented in Table 4. The predictors in the
Table 2 Use of psychotropic drugs at inclusion and discharge (n = 145)
Psychotropic drug: Inclusion (%): Discharge (%:) Mean DDD1 (SD2), inclusion: Mean DDD1 (SD2), discharge:
Antidepressants 74.5 84.1 1.48 (0.91) 1.74 (0.93)
Anxiolytics 22.1 20.0 0.51 (0.35) 0.38 (0.29)
Hypnotics 38.6 36.6 1.01 (0.51) 0.92 (0.26)
Antipsychotics 23.4 27.6 0.42 (0.46) 0.38 (0.26)
Antidementia drugs 2.1 7.6 0.89 (0.38) 0.80 (0.37)
Lithium 4.8 6.9 0.57 (0.24) 0.52 (0.21)
Antiepileptics 9.0 13.1 0.77 (0.54) 0.57 (0.49)
Antiparkinson drugs 2.8 2.1 0.52 (0.22) 0.67 (0.33)
1DDD = Defined daily dose
2SD = Standard deviation
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regression models correlated weakly, except for (higher)
age at onset of the first lifetime depressive episode with
(no) previous depressive episode(s) (Pearson’s correlation
coefficient = 0.65) and having a diagnosis of dementia
with a lower MMSE score (Pearson’s correlation coeffi-
cient = 0.54). According to the bivariate linear mixed
model, having a diagnosis of dementia and lower score
on MMSE were associated with less improvement of the
MADRS score. Only having a diagnosis of dementia was
associated with lower levels of improvement in the mul-
tivariable analysis. In the logistic models, poorer physical
health was associated with a lower response rate in both
the bivariate and the multivariable analyses. An age of
< 60 years at onset of the first lifetime depressive
episode, having previous depressive episode(s), a higher
HADS-A score and lower IADL functioning were associ-
ated with a lower remission rate in the bivariate analysis.
Having a diagnosis of dementia and previous depressive
episode(s) were associated with a lower remission rate in
the multivariable analysis. Among the confounding
variables, a longer stay in hospital (higher number of
days) was associated with a lower response rate in the
multivariable analysis and a lower remission rate in the
bivariate and multivariable analyses.
A sensitivity analysis excluding those patients with a
diagnosis of dementia was performed. The significant
findings in our regression models were not altered.
Discussion
In the present study on the course of depression in hos-
pitalized patients, 74 of the 145 patients (51.0 %) experi-
enced a remission, defined as a total MADRS score of
nine or lower at discharge. A treatment response (a re-
duction of 50 % or more of the MADRS score) was
found in 99 (68.3 %) patients. These figures are compar-
able to the results from similar studies [8, 9], however
the results from prospective observational studies of the
prognosis of hospitalized patients with DLL vary largely
[9]. Our study differs from other observational studies of
DLL in that patients with dementia are included, as we
wanted the study population to be as representative as
possible of the clinical practice of old-age psychiatry in
specialist health care services in Norway.
The main goal in treatment of depressive episodes of
DLL is to attain remission. The remission rate was rela-
tively low at discharge in the present study, and we sug-
gest that there could be several explanations as to why
we and other observational studies of patients with DLL
have found these low remission rates.
Firstly, low remission rates could be related to the
nature of DLL. Our study population included many
patients with DLL who were difficult to treat in primary
care. About half of the patients had comorbidities that
resulted in poor physical health. Nine percent had
dementia, and 40.7 % had a MMSE score below 26 at
inclusion. Our population of old people could present
unspecific symptoms (such as reduced sleep and reduced
appetite) and symptoms of cognitive impairment (like
concentration difficulties) that the MADRS tapped as
depressive, rather than as symptoms of comorbidities,
thus making it harder to attain remission as measured
by the MADRS.
Secondly, the low remission rate could be related to
the treatment offered. The treatment was perhaps not
intensive or long enough for all patients. Several patients
were referred to further treatment in specialist psychi-
atric health care after discharge, but at a lower level of
care than they had received during the study period.
Table 3 The mean score, change in the mean score, intra-class correlation coefficient for change in the mean score, standard
deviation for change in the mean score and effect size of the individual Montgomery and Asberg Depression Rating Scale (MADRS)
items during treatment (n = 145)
MADRS-item: Mean score at
inclusion
Change (decrease) in mean
score
ICC1 for change in
mean score
SD2 for change in score adjusted
for cluster effect
ES3
Apparent sadness 2.55 1.49 4.7 2.08 0.72
Reported sadness 2.98 2.00 12.0 2.26 0.88
Inner tension 3.05 1.53 7.4 2.33 0.66
Reduced sleep 2.41 1.58 1.3 2.65 0.60
Reduced appetite 2.09 1.46 0.6 2.23 0.65
Concentration difficulties 2.73 1.29 6.5 2.56 0.50
Lassitude 3.19 1.86 7.9 2.33 0.80
Inability to feel 2.59 1.57 9.2 2.33 0.67
Pessimistic thoughts 2.89 1.57 0.6 2.46 0.64
Suicidal thoughts 1.69 1.12 9.3 1.45 0.77
1ICC = Intra-class correlation coefficient
2SD = Standard deviation
3ES = Effect size
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Table 4 Regression models with associated predictors for change in Montgomery and Asberg Depression Rating Scale (MADRS) score, response and remission as dependent
variable (n = 122)
Linear mixed model (Change in MADRS score as
dependent variable)
Logistic regression model for hierarchical data
(Response as dependent variable)
Logistic regression model for hierarchical data
(Remission as dependent variable)










p-value OR3 (95 % CI2) p-value OR3 (95 % CI2) p-value OR3 (95 % CI2) p-value OR3 (95 % CI2) p-value
MMSE 0.49 (0.03;0.96) 0.038* 1.10 (0.98;1.23) 0.094 1.05 (0.95;1.17) 0.337
HADS-A 0.14 (−0.25;0.52) 0.482 0.97 (0.88;1.06) 0.443 0.90 (0.83;0.99) 0.024* 0.93 (0.84;1.03) 0.150
Number of drugs 0.10 (−0.47;0.68) 0.720 0.90 (0.79;1.03) 0.117 0.95 (0.84;1.08) 0.445
Previous depressive
episode (s) (Yes as 01)
−0.09 (−3.80;3.63) 0.964 −2.01 (−7.09;3.07) 0.436 1.28 (1.28;3.14) 0.581 3.30 (1.41;7.68) 0.006* 4.61 (1.64;13.01) 0.004*
IADL score 2.11 (−4.81;9.04) 0.547 0.60 (−7.99;6.79) 0.873 2.67 (0.56;12.79) 0.217 5.36 (1.06;27.27) 0.043* 3.82 (0.63;23.20) 0.144
Diagnosis of dementia
(No diagnosis as 01)
−8.26 (−14.19;-2.33) 0.007* −9.03 (−15.40;2.64) 0.006* 0.27 (0.07;1.05) 0.058 0.25 (0.06;1.03) 0.055 0.21 (0.04;1.08) 0.061 0.11 (0.02;0.73) 0.023*
Age at onset of first
lifetime depressive
episode (<60 years as 01)
1.10 (−2.29;4.48) 0.523 3.35 (− 1.28;7.99) 0.154 1.79 (0.80;4.00) 0.157 2.50 (1.17;5.36) 0.019*
Duration of current
depressive episode
(≤12 weeks as 01)
−2.61 (−6.22;1.00) 0.154 −2.40 (−6.14;1.35) 0.207 0.83 (0.35;1.96) 0.667 0.56 (0.24;1.33) 0.184 0.50 (0.20;1.28) 0.147
GMHR (Very good/
good as 01)
−2.23 (−5.67;1.21) 0.202 −1.38 (−4.90;2.13) 0.436 0.35 (0.15;0.79) 0.012* 0.38 (0.16;0.90) 0.029* 0.52 (0.24;1.11) 0.091
Depression with
psychosis according
ICD-10 (no as 01)
3.42 (−2.68;9.52) 0.269 3.42 (−2.86;9.69) 0.283 1.05 (0.24;4.62) 0.946 1.68 (0.42;6.70) 0.458
Age −0.15 (−0.41;0.11) 0.258 −0.28 (−0.57;0.006) 0.055 1.06 (0.99;1.14) 0.064 1.04 (0.97;1.12) 0.232 1.01 (0.95;1.07) 0.731 1.00 (0.93;1.07) 0.983
Years of education 0.06 (−0.53;0.64) 0.850 -0.19 (-0.78;0.41) 0.533 0.91 (0.80;1.04) 0.160 0.92 (0.80;1.05) 0.218 0.95 (0.84;1.08) 0.438 0.94 (0.82;1.09) 0.413
Gender
(Female as 01)
2.58 (−1.26;6.42) 0.187 1.82 (−2.09;5.73) 0.357 0.71 (0.29;1.74) 0.449 0.81 (0.31;2.15) 0.675 1.16 (0.49;2.75) 0.733 0.96 (0.36;2.58) 0.931
Marital status
(Not-single as 01)
−2.28 (−5.69;1.14) 0.189 −2.25 (−5.84;1.33) 0.216 1.20 (0.54;2.69) 0.656 1.01 (0.42;2.40) 0.989 1.24 (0.58;2.66) 0.580 0.86 (0.34;2.17) 0.752
Days of stay in
hospital
−0.02 (−0.06;0.01) 0.216 −0.03 (−0.07;0.004) 0.083 0.99 (0.98;1.00) 0.061 0.99 (0.98;1.00) 0.042* 0.989 (0.979;0.999) 0.026* 0.987 (0.976;0.997) 0.014*
1 = Reference category
2CI = Confidence interval











Some of these patients might have reached remission
after discharge from departments of old-age psychiatry.
The fact that treatment was continued at a lower level of
care when the patients were substantially better, but not
in complete remission, may indicate a well-functioning
health service.
Thirdly, the explanation for a relatively poor outcome in
terms of remission rates could be related to the use of the
MADRS and the definitions of remission and response.
Our definition of remission is in line with previous recom-
mendations [29], but it could be a conservative measure
for inpatients treated for DLL at departments for old-age
psychiatry in specialist health care [18]. A Norwegian
study of the MADRS as a screening tool for DLL found
that the best cut-off was 13/14, as compared to the ICD-
10 criteria for depression [16].
Ultimately, the period of time around discharge can be
a vulnerable period for patients with DLL, and may yield
symptoms that the MADRS taps.
Symptom-specific changes
The highest mean scores at the time of inclusion were ob-
served for the MADRS items “lassitude”, “inner tension”
and “reported sadness”, while the lowest was for the item
“suicidal thoughts.” The effect size of the symptom-
specific effects of treatment is a descriptive, not inferential
measure of change [30]. The MADRS items “reported sad-
ness” (ES = 0.88) and “lassitude” (ES = 0.80) showed the
greatest improvement while “concentration difficulties”
showed the smallest improvement (ES = 0.50) during
treatment in the present study. In a multicenter, placebo-
controlled study of 728 patients with DLL, Nelson et al.
applied symptom-specific effect sizes and examined which
symptoms on the Hamilton Depression Rating Scale
(HRSD) changed the most during Sertraline treatment.
“Depressed mood,” and “decreased interest and activity”
improved the most, while “loss of weight” improved the
least [14]. The study excluded patients with psychotic or
bipolar disorders, a diagnosis of dementia, or a MMSE
score less than 24. Thus, even though the study popula-
tion and assessment scale differ from the present study,
the results are comparable. The symptoms equivalent to
the ICD-10 core symptoms of a diagnosis of depression
(depressed mood to a degree that is definitely abnormal
for the individual, loss of interest or pleasure in activities
that are normally pleasurable, and decreased energy or in-
creased fatigability [21]) improved the most during treat-
ment of DLL [11, 14]. Previous studies indicate that this
may apply to other age groups as well [14, 30]. The
present study showed that “concentration difficulties” im-
proved the least. This may be explained by the fact that a
considerable proportion of the current sample also had
cognitive impairment or dementia, in which concentration
difficulty is a common symptom. From our findings, it
seems that concentration difficulty can be a symptom of
DLL that improves to a lesser extent during treatment.
Clinical predictors
The three regression models yielded different results re-
garding the association between clinical predictors and
the outcomes; the multivariable analyses showed that hav-
ing a diagnosis of dementia was associated with less im-
provement in MADRS score; poorer physical health was
associated with a lower response rate; and having a diag-
nosis of dementia and previous depressive episode(s) were
associated with a lower remission rate. This underlines
that response (assessed as continuous or dichotomous
variables) and remission are different outcomes. Indeed,
we found that 31.3 % of the responders did not experience
a remission.
It can be difficult to distinguish between the effects at-
tributable to the number of depressive episodes and
those attributable to age at the first lifetime onset of de-
pressive episode [26]. In our data these two predictors
exhibited a strong association (Pearson’s correlation co-
efficient of 0.65). Having previous depressive episode(s)
became the strongest predictor of a lower remission rate
in the multivariable analysis. Driscoll et al. have de-
scribed that when recurrent episodes of depression oc-
curred, they most likely were more complicated to treat
than the first episode of depression among DLL patients
[32]. A recent study has described that a first lifetime
onset of depression in early life (EOD) was associated
with more severe depressive symptoms and more re-
sidual symptoms over time, and that a first lifetime onset
of depression in later life (LOD) was associated with
more cognitive and neurological changes [17]. However,
the definitions of EOD and LOD, study populations, and
the assessment of outcomes all differ, and there is no
clear consensus in the literature of how a patient’s age at
the onset of first lifetime depression predicts outcome in
depressive episodes [17, 26, 33–36]. Our findings con-
firm previous studies showing that recurrent episodes of
depression among DLL patients might be more difficult
to treat.
DLL and comorbid anxiety commonly coexist. Studies
have found that a greater severity of anxiety symptoms
can have a negative impact on acute treatment response
in late-life depression [11, 37, 38]. Our findings on the
association between anxiety and a lower remission rate
in the bivariate analysis might support the view that
attaining remission in DLL patients with severe anxiety
can be difficult. However, this association between anx-
iety and remission was not significant in the multivari-
able analysis.
In the present study, worse physical health was signifi-
cantly associated with a worse outcome in terms of re-
sponse. Our finding is in line with previous findings,
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showing that a high medical burden can complicate the
treatment of DLL [2, 8, 11].
In addition, having a diagnosis of dementia was
strongly associated with less improvement in the
MADRS score during treatment. Having a diagnosis of
dementia was also associated with lower remission in
the multivariable analysis. As only 9.0 % of the study
population had a diagnosis of dementia, it is hard to
draw any clear conclusions, but the results may indicate
that patients with dementia were less responsive to treat-
ment. Previous studies have described decreased treat-
ment response in patients with depression and dementia
[39]. Some possible reasons for this relationship can be
that depression in patients with dementia may have a
different neurobiology from depression in those without
dementia. Further, it is difficult to define homogenous
groups of patients with depression and dementia. Also,
there is evidence that subgroups of patients with cognitive
impairment (e.g. with a severe burden of white matter
hyperintensities) have unfavorable responses to antide-
pressants [11, 40]. Cognitive impairments in DLL could
persist even after remission of depression [41] and symp-
toms of cognitive impairments and DLL can overlap.
Limitations and strengths
The study population was heterogeneous, as there was a
great variation in the degree of depressive symptoms as
measured by the MADRS, cognitive impairment, and
the days of the patients’ stay in hospital. Thus, we
treated the days of patients’ stay in hospital as a con-
founder in the analysis. The study was observational,
and treatment was not standardized but varied according
to local treatment regimen and patients’ different needs.
It is therefore difficult to generalize the results to a spe-
cific group of DLL patients.
Some of the study centers could not include patients
for the entire duration of the study period, due to
reorganization of health services.
The study was performed in a multicenter setting with
different assessors, which could influence inter-rater reli-
ability. However, the MADRS is shown to have good
inter-rater reliability among different health professionals
[15], and this scale is recommended for use in assessing
depression in Norway [42]. Furthermore, the assessors
participated in structured training in the use of assessment
scales both prior to and during the study. Moreover, the
statistical models used have been adjusted for the possible
cluster effect due to the multicenter design.
The MADRS has the best validity for patients without
dementia or with mild dementia [16]. In the present
study population there were 13 patients with a diagnosis
of dementia; and among these the mean MMSE score
was 20.1 (SD = 3.6). Thus, the MADRS would be a valid
tool to assess DLL in most patients in this study.
The mean number of days from admission to inclusion
was 5.7 (SD = 6.0). It could be that for some of the pa-
tients, the depressive symptoms had changed between
the time of admission and the time they were assessed.
A strength of the study is the use of well-established
assessment scales. In order to reflect clinical, everyday
practice, the inclusion criteria were broad, and the de-
sign of the study was observational and prospective.
Thus, the study will have high clinical relevance for pa-
tients with DLL who are admitted to hospital.
Conclusions
This observational study of DLL in hospitalized patients
showed that at discharge the response rate was higher
than the remission rate, according to our definitions.
“Reported sadness” and “lassitude” were the items on
the MADRS that showed the greatest amount of im-
provement during treatment.
Recurrent episodes of depression, poor somatic health,
and a diagnosis of dementia were found to be important
negative prognostic factors for the course of DLL. Clini-
cians should pay close attention to these factors when
planning and evaluating treatment.
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